MX2019013207A - Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis. - Google Patents

Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.

Info

Publication number
MX2019013207A
MX2019013207A MX2019013207A MX2019013207A MX2019013207A MX 2019013207 A MX2019013207 A MX 2019013207A MX 2019013207 A MX2019013207 A MX 2019013207A MX 2019013207 A MX2019013207 A MX 2019013207A MX 2019013207 A MX2019013207 A MX 2019013207A
Authority
MX
Mexico
Prior art keywords
endometriosis
methods
compositions
treating
associated symptoms
Prior art date
Application number
MX2019013207A
Other languages
English (en)
Inventor
Eric Gross
Daria Mochly-Rosen
Stacy Lynn Mcallister
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2019013207A publication Critical patent/MX2019013207A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/364—Endometriosis, i.e. non-malignant disorder in which functioning endometrial tissue is present outside the uterine cavity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Se proveen métodos y composiciones para el tratamiento de endometriosis en un individuo, y el dolor asociado a la endometriosis. Los aspectos de los métodos incluyen la administración al individuo de un agente que promueve la actividad de ALDH.
MX2019013207A 2017-05-05 2018-05-03 Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis. MX2019013207A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762502310P 2017-05-05 2017-05-05
US201862643591P 2018-03-15 2018-03-15
PCT/US2018/030924 WO2018204673A1 (en) 2017-05-05 2018-05-03 Methods and compositions for treating endometriosis and endometriosis associated symptoms

Publications (1)

Publication Number Publication Date
MX2019013207A true MX2019013207A (es) 2020-07-14

Family

ID=64016457

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013207A MX2019013207A (es) 2017-05-05 2018-05-03 Metodos y composiciones para tratar la endometriosis y sintomas asociados a la endometriosis.

Country Status (7)

Country Link
US (2) US20200179334A1 (es)
EP (1) EP3619317A4 (es)
BR (1) BR112019023228A2 (es)
CA (1) CA3062529A1 (es)
MX (1) MX2019013207A (es)
TW (1) TW201904571A (es)
WO (1) WO2018204673A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115804762B (zh) * 2022-12-20 2024-05-31 浙江大学 一种巨噬细胞膜包覆的异位子宫内膜靶向纳米粒、制备方法及应用
WO2024229242A2 (en) * 2023-05-02 2024-11-07 Cedars-Sinai Medical Center Methods of treating endometriosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110082180A (ko) * 2008-10-28 2011-07-18 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 알데히드 탈수소효소의 조절자 및 그것의 사용방법
US9545393B2 (en) * 2012-08-24 2017-01-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating pain
KR102319882B1 (ko) * 2014-02-19 2021-11-03 아비브 테라퓨틱스, 인크. 암의 치료를 위한 폴리사이클릭 아미드와 결합하는 미토콘드리아 알데히드 탈수소효소 2 (aldh2) 및 그의 용도

Also Published As

Publication number Publication date
EP3619317A1 (en) 2020-03-11
BR112019023228A2 (pt) 2020-05-19
WO2018204673A1 (en) 2018-11-08
US20200179334A1 (en) 2020-06-11
US20220233498A1 (en) 2022-07-28
EP3619317A4 (en) 2021-01-20
TW201904571A (zh) 2019-02-01
US11974981B2 (en) 2024-05-07
CA3062529A1 (en) 2018-11-08

Similar Documents

Publication Publication Date Title
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2025009223A (es) Agentes de union a clec9a y su uso
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX387885B (es) Inhibidores de ezh2 para tratar linfomas.
PH12016500840A1 (en) Methods of using interleukin-10 for treating diseases and disorders
PH12019501010A1 (en) Arginase inhibitor combination therapies
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2017007321A (es) Terapias de combinacion.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
ZA201800056B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MY187540A (en) Compounds active towards bromodomains
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX383893B (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar el cáncer.
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2020011817A (es) Metodos para tratar el linfoma.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MX380835B (es) Terapia de combinación pac-1.